8-K Announcements
6Material company update
Mar 27, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Nov 3, 2025·SEC
ABVC BioPharma, Inc.(ABVC)Earnings, Financials & Key Ratios
ABVC•NASDAQ
$1.53
Price updated Jun 27, 2026
AboutABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.Show more
- Revenue$0-100.0%
- EBITDA-$7M-47.6%
- Net Income-$8M-61.3%
- EPS (Diluted)-0.39+7.1%
- ROE-112.81%+77.3%
ABVC Price & Volume
ABVC BioPharma, Inc. (ABVC) stock price & volume — 10-year historical chart
Loading chart...
Stalled Revenue Growth Masks Severe Liquidity Constraints
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"ABVC BioPharma faces a precarious outlook characterized by a total absence of sustainable revenue and a reliance on sporadic milestone payments that have failed to materialize. The company's heavy reliance on high SG&A expenses, which frequently exceed $1.5 million per quarter, continues to outpace R&D investment and exacerbate cash burn. Investors should remain cautious as the firm's cash reserves have dwindled to approximately $140,300, creating an imminent risk of dilutive financing to maintain clinical operations."
Verdict Logic
the company's cash reserves of approximately $140,300 against a current ratio of 0.12 suggest an imminent liquidity crisis and high probability of shareholder dilution.
ABVC Growth Metrics
ABVC BioPharma, Inc. (ABVC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-256.56%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-441.01%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM19.54%
Return on Capital
10 Years-540.82%
5 Years-189.67%
3 Years-211.5%
Last Year-90.06%
ABVC Recent Earnings
ABVC BioPharma, Inc. (ABVC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (25%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 18, 2026Metric
Actual
Est
EPS
$0.06
—
Rev
—
—
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.12
—
Rev
$795,950
—
Q4 2025
Oct 31, 2025Metric
Actual
Est
EPS
$0.05
—
Rev
$795,950
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.13
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $0.06 | — |
| Q2 2026 | Mar 3, 2026 | $0.12 | $795,950 |
| Q4 2025 | Oct 31, 2025 | $0.05 | $795,950 |
| Q3 2025 | Aug 13, 2025 | $0.13 | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for ABVC BioPharma, Inc. (ABVC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.53 | $22.17M | -3.92 | -100% | — | -112.81% | — | |
| $4.34 | $17.12M | -0.17 | — | — | -381.01% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — | |
| $2.17 | $17.58M | -1.00 | 1.84% | -60.17% | -148.91% | — |
Compare ABVC vs Peers
ABVC BioPharma, Inc. (ABVC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABVC SEC Filings & Documents
ABVC BioPharma, Inc. (ABVC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ABVC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABVC Frequently Asked Questions
ABVC BioPharma, Inc. (ABVC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is ABVC BioPharma, Inc.'s revenue?
ABVC BioPharma, Inc. (ABVC) reported $-0.8M in revenue for fiscal year 2025. This represents a 8060% decrease from $0.0M in 2002.
How fast is ABVC BioPharma, Inc. growing?
ABVC BioPharma, Inc. (ABVC) saw revenue decline by 100.0% over the past year.
Is ABVC profitable?
ABVC BioPharma, Inc. (ABVC) reported a net loss of $9.4M for fiscal year 2025.
Dividend & Returns
What is ABVC's return on equity?
ABVC BioPharma, Inc. (ABVC) has a return on equity (ROE) of -112.8%. Negative ROE indicates the company is unprofitable.
What is ABVC BioPharma, Inc.'s free cash flow?
ABVC BioPharma, Inc. (ABVC) had negative free cash flow of $3.3M in fiscal year 2025, likely due to heavy capital investments.